gutflix
GI learning, personalised

Summary

MH002, AN OPTIMIZED LIVE BIOTHERAPEUTIC PRODUCT, PROVIDES EFFICACY IN ACUTE POUCHITIS: RESULTS FROM A PILOT STUDY

Franco Scaldaferri

UEG Week Vienna 2024 | Presentation

IBD | Mechanisms & Personalised Medicine

October 14, 2024

In this open-label pilot study of 13 patients with acute pouchitis, 8 weeks of treatment with MH002, a consortium of 6 commensal bacteria, achieved modified PDAI remission in 46% and was safe and well tolerated with no adverse reactions.

KEY POINTS

- At week 8, 6/13 (46%) subjects achieved mPDAI remission, defined as mPDAI less than 5 and a reduction of at least 2 points from baseline
- Symptomatic response, endoscopic response, and histologic response were achieved in 5/13 (39%), 5/13 (39%), and 2/13 (15%) subjects, respectively
- In the subgroup achieving remission, median faecal calprotectin decreased by 68%, 71%, and 80% at weeks 2, 4, and 8, respectively
- MH002 was safe and well tolerated with no adverse reactions; two serious adverse events (hypertension and perianal abscess) were unlikely drug-related
- Improvement in severity of urgency was reported by 8/13 (62%) subjects at week 8, and Robarts Histopathologic Index improved in 9/13 (69%) subjects
- The authors conclude these results warrant further development of MH002 in a phase 2/3 study for acute pouchitis, a condition with no currently approved treatment

VIEW THIS CONTENT ON GUTFLIX

https://gutflix.eu/search/d/110422b6-9112-11ef-8f95-0242ac140004

AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.